Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a trial for patients affected by metastatic or relapsed osteosarcoma which progressed
after first or further line treatments. In this trial, all patients will be treated until
progression or unacceptable toxicity with sorafenib and everolimus. The treatment with
sorafenib and everolimus aimed to obtain a 50% rate of patients free from further progression
of the disease after 6 months from study entry.